RxDoctor Payments Data

Musaab Zaid, MD

Internal Medicine · Richardson, TXNPI 1730473182

Payments from drug & device makers

$138in general payments, 2019–2025

Across 6 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$54
  • Johnson & Johnson$43
  • Novartis$17
  • Pfizer$13
  • Merck$11

What the payments were for

  • Food & beverage$138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker1$54
Johnson & Johnson2$43
Novartis1$17
Pfizer1$13
Merck1$11

How this compares

$138 in reported general payments places this provider in the 35th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$1,704,359
Medicare patients
1,457
Services billed
20,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban400$120,097
IngrezzaValbenazine Tosylate12$48,550
XareltoRivaroxaban70$20,314
XifaxanRifaximin11$17,637
JardianceEmpagliflozin55$14,943
Pantoprazole Sodium247$10,015
RytaryCarbidopa/Levodopa17$8,842
Atorvastatin Calcium526$7,708
MyrbetriqMirabegron32$7,384
TradjentaLinagliptin27$7,286
GemtesaVibegron30$7,097
EntrestoSacubitril/Valsartan20$6,998
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$6,852
Gabapentin305$5,952
Potassium Chloride206$5,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$120,097400 claims
Johnson & JohnsonXarelto$43$20,31470 claims
NovartisEntresto$17$6,99820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →